Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
High Attention Score compared to outputs of the same age and source (81st percentile)
Readers on
- mendeley
- 57 Mendeley